[REVISION HISTORY]

Evolution of obesity medication treatments

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-10-16 13:22 UTC → 2026-10-17 16:44 UTC · added ~~removed~~

The landscape of obesity treatments is shifting toward more convenient delivery methods, specifically weekly injections and oral therapies. In the United States, Viking Therapeutics is preparing to begin phase 3 clinical trials for its oral formulation, VK2735, following phase 2 results where patients lost up to 12.2% of body weight over 13 weeks. Meanwhile, Australian regulators are reviewing approval processes for similar oral medications. In Europe, the European Medicines Agency has approved the molecule orforglipron, which is expected to enter commercial markets soon. During the ‘SIO WiP – Obesity Work in Progress’ national congress in Palermo, medical experts discussed how these developments are expected to facilitate commercialization in various nations, including Italy. Oral therapies are viewed as a significant advancement for patient convenience, helping to overcome “psychological barriers associated with needle-based treatments.” Medical experts note that these incretin-based medications offer secondary benefits, such as improved cardiovascular health and reduced risks of sleep apnea. However, professionals emphasize that obesity is a chronic condition requiring long-term management to prevent weight regain, and they continue to monitor potential oncological risks and side effects.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.